HealthTree Logo
search more_vert
person Sign In / Create Account

Rachid C. Baz, MD

Multiple Myeloma Specialist

location_city Moffitt Cancer Center

17 years treating Multiple Myeloma

Clinical Expertise

  • Multiple Myeloma 


Dr. Baz has developed a special expertise in managing patients with plasma cell disorders such as multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), plasmacytoma, primary systematic amyloidosis, and Waldenstrom's macroglobulinemia (WM). Dr. Baz is a very active researcher in the field and is involved in a number of clinical trials as well as the Moffitt Myeloma Working Group (MMWG). He is a frequent lecturer on myeloma for both medical and lay audiences. Dr. Baz’s research focuses on malignant hematology and involves the development and implementation of biomarker-driven therapeutics into patient-based phase I and II clinical trials, including early-phase clinical trials in multiple myeloma. In this context, he and his colleagues initiated a clinical trial of a response-adapted therapy in newly diagnosed myeloma patients who are not candidates for high-dose therapy and do not have high-risk disease. He and his team are evaluating several novel agents (novel proteasome inhibitors, novel immunomodulators as well as monoclonal antibodies). Moreover, Dr. Baz has collaborated with outcome researchers (focusing on outcomes to therapy as well as defining optimal sequences of therapy) and with basic scientists (focusing on translational research and new drug development in myeloma).


Moffitt Cancer Center: 12903 USF Magnolia Drive, Tampa, FL 33612, USA

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Bristol Myers Squibb

Follow Us

facebook twitter